The role of antiplatelet therapy in aneurysm coiling. (April 2014)

• Record Type: Journal Article
• Authors: Rahme, Rudy J.; Zammar, Samer G.; El Ahmadieh, Tarek Y.; El Tecle, Najib E.; Ansari, Sameer A.; Bendok, Bernard R.
• Is Part Of: Neurological research. Volume 36:Number 4(2014)
• Page Start: 383
• Page End: 388
• Publication Date: 2014-04
• Subjects: Neurology -- Periodicals; Neurosciences -- Periodicals; 616.8005
• DOI: 10.1179/1743132814Y.0000000317
• Languages: English
• ISSNs: 0161-6412

Abstract

<abstract> <title> <x content-type="archive" xml:space="preserve">Abstract</x> </title> <sec> <p>Neurointerventional surgery offers the potential to deliver remarkable intravascular therapies for various neurovascular diseases and stroke. This approach, however, carries a risk of complications that need to be kept to a minimum. Thromboembolism is one of the most consequential complications of neurointerventional surgery in the treatment of intracranial aneurysms. Both antiplatelet and anticoagulant therapies have shown to reduce the risk of thromboembolism in this setting. In this paper, we review the role of antiplatelet therapy in the endovascular management of intracranial aneurysms. For unruptured aneurysms, the use of antiplatelet agents to pre-medicate patients before and during the procedure appears safe and effective in reducing the thrombotic risk. Abciximab has not been extensively studied, but seems to be safe as a salvage maneuver in the case of thrombus formation even in ruptured aneurysms (when the dome is relatively secure) with low rates of intraprocedure and procedure hemorrhagic complications. Further innovation and research are needed to further reduce thromboembolic risks of aneurysm coiling.</p> </sec> </abstract>